US · Healthcare · Medical Devices
EPS came in at 2.59 against a street estimate of 2.54 — a beat of 2.0%.
Analysts rate STERIS plc a buy (5 buy, 5 hold, 0 sell out of 10) with an average price target of $263.12.
CONFIDENT STERIS posted 6% organic growth in Q1 FY27 with margin expansion and strong cash flow. Announced $600M North Carolina chemistry facility, largest single-site investment ever. Maintained full-year guidance despite AST inventory destocking headwinds. Q1 FY27 No regional breakouts provided in call. Analysts pressed AST recovery timing, NC facility rationale, and Life Sciences onshoring trends. Management confident in H2 acceleration, emphasized automation benefits and pharma localization tailwinds, but acknowledged endoscopy surge sustainability uncertain. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.26% |
| Vanguard Capital Management, LLC | 6.53% |
| State Street Corp | 5.12% |
| Vanguard Portfolio Management, LLC | 5.08% |
| Morgan Stanley - Brokerage Accounts | 4.51% |
| Massachusetts Financial Services Company | 4.11% |
| Wellington Management Company LLP | 3.59% |
| Orbis Allan Gray Ltd | 2.66% |
| Document | Date |
|---|---|
| Quarterly report · Q1 FY2027 STERIS PLC - FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total Revenues (Q1 FY2027): $1,492.7 million, up 7.3% vs. $1,391. | 2026-08-07 |
| Shareholder vote results · Q2 FY2027 STERIS PLC – 8-K FILING SUMMARY (July 31, 2026) HEADLINE NUMBERS • 97,457,680 ordinary shares outstanding and entitled to vote at the Annual General | 2026-08-06 |
| Results announced · Q2 FY2027 STERIS PLC – FISCAL 2027 Q1 RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $1,492.7 million, up 7% year-over-year (constant currency organic grow | 2026-08-05 |
| Proxy statement · Q2 FY2027 STERIS PLC PROXY STATEMENT SUMMARY HEADLINE NUMBERS • Full year fiscal 2026 revenues increased 8.7% to $5,935.9 million, compared with $5,459.5 mill | 2026-06-11 |
| Annual report FY2026 STERIS PLC - FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (non-affiliate shares as of Sept 30, 2025): $24,222.3 m | 2026-05-29 |
| Results announced · Q1 FY2027 STERIS PLC – FISCAL 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Full year fiscal 2026 revenue from continuing operations: $5.9 billion, up 9% | 2026-05-11 |
| Board / officer change · Q1 FY2027 STERIS PLC - 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 9 to 10 members as of May 5, 2026 • One director departing after 18 years of s | 2026-05-07 |
| Quarterly report · Q3 FY2026 STERIS PLC - FORM 10-Q SUMMARY For Quarter Ended December 31, 2025 --- HEADLINE NUMBERS • Total Revenues (9 months): $4,347.5 million vs. $3,979.0 | 2026-02-06 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.69 / share ex-date Sep 4, 2026 · pay Sep 25, 2026 | 2026-09-04 |
| Dividend | $0.63 / share ex-date Jun 8, 2026 · pay Jun 26, 2026 | 2026-06-08 |
| Dividend | $0.63 / share ex-date Feb 17, 2026 · pay Mar 19, 2026 | 2026-02-17 |
| Dividend | $0.63 / share ex-date Nov 18, 2025 · pay Dec 18, 2025 | 2025-11-18 |
| Dividend | $0.63 / share ex-date Sep 4, 2025 · pay Sep 26, 2025 | 2025-09-04 |
| Announcement | Date |
|---|---|
| Manufacturing consolidation plan with new Center of Excellence in North Carolina STERIS announced a manufacturing consolidation plan on August 5, 2026, to centralize formulated chemistry production and distribution to a new Center of Excellence in North Carolina. The com | 2026-08-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for STERIS plc — free to start.
Google PlayApp StoreData updated 2026-09-18.